Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities: 2019-2025

  • China SXT Pharmaceuticals' Total Non-Current Liabilities fell 46.89% to $158,263 in Q3 2025 from the same period last year, while for Sep 2025 it was $158,263, marking a year-over-year decrease of 46.89%. This contributed to the annual value of $211,683 for FY2025, which is 28.16% down from last year.
  • According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Total Non-Current Liabilities is $158,263, which was down 25.24% from $211,683 recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Non-Current Liabilities peaked at $365,823 during Q1 2023, and registered a low of $6,292 during Q1 2021.
  • Over the past 3 years, China SXT Pharmaceuticals' median Total Non-Current Liabilities value was $296,339 (recorded in 2024), while the average stood at $273,326.
  • Data for China SXT Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY slumped of 82.77% (in 2021) over the last 5 years.
  • China SXT Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $6,292 in 2021, then reached $311,512 in 2023, then declined by 4.33% to $298,011 in 2024, then crashed by 46.89% to $158,263 in 2025.
  • Its last three reported values are $158,263 in Q3 2025, $211,683 for Q1 2025, and $298,011 during Q3 2024.